Figure 1.
Investigating the c.1516G > T;p.E506* MRE11A variant in two unrelated HBOC patients of French-Canadian origins. (a) (i) and (ii) H&E staining of the two probands’ breast (invasive ductal carcinoma; IDC) and ovarian tumors (high grade serous carcinoma; HGSC), respectively. (iii) and (iv) Immunohistochemistry staining demonstrating the MRE11A protein expression levels in the two probands’ tumors. (b) Schematic representation of the identified variant’s position within the MRE11A protein. (c) Cycloheximide chase assay showing that the identified variant undergoes nonsense-mediated mRNA decay, as denoted by the arrow, in the Family A proband-derived lymphoblastoid cell line. (d,e) Pedigrees of Family A and B, respectively. Carriers of c.1516G > T;p.E506* MRE11A are indicated by + and probands are indicated by arrows. (f) Contribution of the different COSMIC single base substitution (SBS) mutational signatures. The SBS3, the Homologous Repair Deficiency (HRD)-associated mutational signature, is indicated by an arrow. (Pedigrees were generated by the PhenoTips opensource https://phenotips.com/index.html).